ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years
Kannan Thanikachalam
Matched on ORCID iD 0000-0001-5379-8966; OpenAlex author ID A5082863672. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 2 papers
Papers 5
- Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
- Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Co-author DOI 10.3389/fonc.2025.1544928↗
- Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
- Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
- Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000688↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Upender Manne Manne · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Ashwini Kumar Esnakula · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Wancai Yang · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Lianbo Yu · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Ankur Sheel · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Ashish Manne · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Jordan M. Cloyd · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Anup Kasi · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Ravi Kumar Paluri · 3 shared papers, 2024–2025 · strength 0.51
- Paper Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. DOI 10.3389/fonc.2025.1544928↗
- Paper Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. DOI 10.3390/ijms25169041↗
- Paper Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy DOI 10.20944/preprints202409.0945.v1↗
- Deepak Sherpally · 2 shared papers, 2024–2025 · strength 0.36
- Sameek Roychowdhury · 2 shared papers, 2024 · strength 0.31
- Mary E. Dillhoff · 2 shared papers, 2024 · strength 0.31
- Anne M. Noonan · 2 shared papers, 2024 · strength 0.31
- Aslam M. Ejaz · 2 shared papers, 2024 · strength 0.31
- Shafia Rahman · 2 shared papers, 2024 · strength 0.31
- Timothy Michael Pawlik · 1 shared paper, 2025 · strength 0.21
- Davendra P. S. Sohal · 1 shared paper, 2024 · strength 0.15
- Eric David Miller · 1 shared paper, 2024 · strength 0.15
- Kenneth L Pitter · 1 shared paper, 2024 · strength 0.15
- David Kwon · 1 shared paper, 2020 · strength 0.11
- Gazala Naaz Khan · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.